Promising preventive and therapeutic effects of TaibUVID nutritional supplements for COVID-19 pandemic: towards better public prophylaxis and treatment (A retrospective study).

Autor:	El Sayed SM; Department of Clinical Biochemistry and Molecular Medicine, Taibah Faculty of Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.; Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University Egypt.; Prophetic Medicine and Integrative Medicine Course and Research, Taibah Faculty of Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia., Aboonq MS; Department of Medical Physiology, Taibah Faculty of Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia., El Rashedy AG; Department of Gastroenterology and Infectious Diseases, Sohag Fever Hospital Sohag, Egypt., Aljehani YT; Director of The Research and Studies Department of Health Affairs in Al-Madinah Region, Consultant Family Medicine and Trainer in Family Medicine Program for Postgraduate Studies Al-Madinah Al-Munawwarah, Saudi Arabia., Abou El-Magd RM; Department of Psychiatry, Faculty of Medicine and Dentistry, University of Alberta Edmonton, Alberta, Canada.; Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications Alexandria, Egypt., Okashah AM; Academic Affairs Director and Consultant Clinical Immunologist, Al-Madinah Directorate of Health, Al-Madinah Al-Munawwarah, Ministry of Health Saudi Arabia., El-Anzi ME; Diabetic Center in King Fahd Hospital & Sayed Al-Shohada Primary Health Care Center Al-Madinah Al-Munawwarah, Saudi Arabia., Alharbi MB; Head of Training and Academic Affairs and Designated Institutional Official (DIO), King Fahad Hospital, Al-Madinah and Leader of Training and Academic Affairs Taskforce Al-Madinah Al-Munawwarah, Saudi Arabia., El-Tahlawi R; Department of Microbiology, College of Medicine, Taibah University Saudi Arabia.; Department of Microbiology, Faculty of Medicine, Zagazig University Egypt., Nabo MMH; Division of Pediatric Cardiology, Pediatrics Department, Maternity and Children Hospital Hail, Saudi Arabia.; Division of Pediatric Cardiology, Pediatrics Department, Sohag Teaching Hospital Sohag, Egypt., Yousef RS; Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University Egypt., Elshazley M; Department of Medicine, Taibah Faculty of Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.; Department of Occupational Diseases and Toxigenomics, Sohag Faculty of Medicine, Sohag University Egypt., Abu-Elnaga M; Department of Anatomy, College of Medicine, King Abdul-Aziz University Jeddah, Saudi Arabia.; Department of Anatomy, Faculty of Medicine, Al-Azhar University Egypt., Mahmoud HS; Center of Scientific Foundation for Experimental Studies and Research Ismailia, Egypt., El-Alaf H; Department of Physiology, Faculty of Medicine, Sohag University Egypt., Abdelrahman AI; Department of Diagnostic Radiology, Zagazig Faculty of Medicine, Zagazig University Egypt., Abdel-Gawad AR; Department of Clinical Pathology, Sohag Faculty of Medicine, Sohag University Egypt., Soliman TM; Department of Clinical Pathology, Sohag Faculty of Medicine, Sohag University Egypt.
Jazyk:	angličtina
Zdroj:	American journal of blood research [Am J Blood Res] 2020 Oct 15; Vol. 10 (5), pp. 266-282. Date of Electronic Publication: 2020 Oct 15 (Print Publication: 2020).
Abstrakt:	Adjuvant nutritional treatment is a commonly overlooked topic when treating lethal viral diseases as COVID-19 pandemic. We recently introduced TaibUVID nutritional supplements (nigella sativa, chamomile and natural honey) as adjuvants for COVID-19 contacts, patients and public prophylaxis. TaibUVID Forte adds costus, senna and fennel to TaibUVID. Meta-analyses and systematic reviews confirmed evidence-based therapeutic benefits of TaibUVID components in treating many human diseases e.g. diabetes mellitus and hypertension, common co-morbidities in COVID-19 patients. Double-blind clinical trials for treating COVID-19 patients with TaibUVID supplements were inapplicable. In this retrospective study in Egypt, COVID-19 patients and contacts knew TaibUVID via social media and voluntarily used them. 65% of COVID-19 patients (n = 13) received both pharmacological treatments and adjuvant TaibUVID nutritional supplements. 35% (n = 7) received TaibUVID only. Lymphopenia rapidly improved to lymphocytosis upon regular TaibUVID intake. TaibUVID nutritional supplements helped COVID-19 contacts' prophylaxis. 70% of COVID-19 contacts (n = 14) (on regular TaibUVID intake) did not get SARS-COV2 infection. 30% (n = 6) were not using TaibUVID regularly and got mild flu-like symptoms and upon using both TaibUVID and pharmacological treatments, all improved and got negative nasopharyngeal swabs PCR. COVID-19 contacts were mainly physicians (40%, n = 8) (dealing with COVID-19 patients daily) and members of physicians' families (45%). Main presentations reported by COVID-19 patients (n = 20) were cough (90%), fever (55%), anosmia (45%), taste loss (45%), sore throat (45%), respiratory difficulty (45%) and malaise (35%). TaibUVID inhalation therapy (nigella sativa/anthemis/costus solution nebulization) was used by 65% of COVID-19 patients (n = 13) and alleviated respiratory manifestations e.g. cough and respiratory difficulty and was life-saving in some cases. 70% of COVID-19 patients (n = 14) improved in 1-4 days, 25% (n = 5) improved in 5-10 days while 5% improved in more than 10 days. TaibUVID nutritional supplements were tolerable and significantly satisfactory (P<0.01). 81.25% of COVID-19 patients (n = 13) did not report side effects. 18.25% (n = 3) reported mild diarrhea, sweating and hyperglycemia (not confirmed to be due to TaibUVID supplements). 31.25% of patients (n = 5) were satisfied by 100% with TaibUVID nutritional supplements. 37.5% (n = 6) of patients were satisfied by 75%. In conclusion, TaibUVID nutritional supplements are recommended for public prophylaxis (to decrease emergence of new cases) and treatment in COVID-19 pandemic. Clinical trials and further investigations are recommended. Competing Interests: None. (AJBR Copyright © 2020.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu